Google
MAZE — MAZE THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
MAZE FAQ
What is MAZE's ROE?
MAZE THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -35.86%.
What is MAZE's dividend yield?
MAZE THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is MAZE's Deepscope Quality Score?
Deepscope rates MAZE's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MAZE?
Deepscope's AI Timing Score for MAZE is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MAZE belong to?
MAZE THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 25.40
Price
0.54
(2.17%)
Day Change
|
|
|---|
MAZE, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 25.40 |
| PBV / Sector |
4.03 / 4.58
|
| Earning Per Share | -2.26 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
11.32 M
GREAT
|
| Average 1W Daily Value |
11.16 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:04 |
| Symbol | MAZE |
| Name | MAZE THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 55.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,375.88 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
Phone: 650 850 5070
Website: https://www.mazetx.com
Employees: 141
Sector: Healthcare >> Biotechnology
Description: Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
